Investors

Announcements
2013
2012
31: Share Capital and Votes
30: Financial calendar 2013
29: BioPorto’s NGAL cutoff patent is issued in China
28: New shares admitted to trading, the company’s financial situation restored
27: BioPorto completes cash issue, private placement
26: BioPorto’s The NGAL Test ™ registered for diagnostic use in Russia – status on progress in the BRIC countries
25: Increase of the share capital through a cash issue, private placement
24: Annoucement from major shareholder
23: BioPorto enters agreement on sales cooperation with Siemens
22: Interim financial report for Q3
21: Cash issue, private placement cancelled, the company in an economically critical state
20: Decision on cash issue, private placement postponed to November 2, 2012
19: Cash issue, private placement delayed
18: BioPorto’s patent rights for NGAL - opposition to the European trauma patent
17: Cash issue, private placement to be carried out
16: Insider's dealings
15: Increase of the share capital through a cash issue, private placement
14: Interim report for Q2 2012
13: Ruling on NGAL patent appealed to the Supreme Court
12: BioPorto obtains its first NGAL patent in the US
11:BioPorto wins lawsuit filed against Phadia
10: BioPorto enters into an agreement with Wiener Lab Group – Status for the distribution of The NGAL Test
09: Interim report Q1 2012
08: BioPorto’s NGAL cut-off patent: assessment of the decision in the opposition case
07: BioPorto’s NGAL cut-off patent: written decision in the opposition case
06: Development of Annual General Meeting
05: Annual General Meeting
04: The NGAL test registered for diagnostic use in China
03: Annual report 2011
02: BioPorto’s NGAL cut-off patent rejected following a decision in the opposition case
01: Announcement from major shareholder
2011
2010
2009
2008
2007
2006
2005
2004
Presentations
Key Figures
Financial Calendar 2013
Analyst coverage
Company Documents
News mail
Contact investor relations